These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11895437)

  • 1. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant.
    Lindberg J; Sigurdsson S; Löwgren S; Andersson HO; Sahlberg C; Noréen R; Fridborg K; Zhang H; Unge T
    Eur J Biochem; 2002 Mar; 269(6):1670-7. PubMed ID: 11895437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
    Ren J; Milton J; Weaver KL; Short SA; Stuart DI; Stammers DK
    Structure; 2000 Oct; 8(10):1089-94. PubMed ID: 11080630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
    Hsiou Y; Ding J; Das K; Clark AD; Boyer PL; Lewi P; Janssen PA; Kleim JP; Rösner M; Hughes SH; Arnold E
    J Mol Biol; 2001 Jun; 309(2):437-45. PubMed ID: 11371163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and energetic analyses of the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogues.
    Udier-Blagović M; Tirado-Rives J; Jorgensen WL
    J Med Chem; 2004 Apr; 47(9):2389-92. PubMed ID: 15084137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
    Cocuzza AJ; Chidester DR; Cordova BC; Klabe RM; Jeffrey S; Diamond S; Weigelt CA; Ko SS; Bacheler LT; Erickson-Viitanen SK; Rodgers JD
    Bioorg Med Chem Lett; 2001 Jun; 11(11):1389-92. PubMed ID: 11378361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
    Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
    SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus.
    Zhou Z; Liu T; Wu G; Kang D; Fu Z; Wang Z; De Clercq E; Pannecouque C; Zhan P; Liu X
    Org Biomol Chem; 2019 Mar; 17(12):3202-3217. PubMed ID: 30839042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
    ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.
    Lai MT; Munshi V; Lu M; Feng M; Hrin-Solt R; McKenna PM; Hazuda DJ; Miller MD
    Viruses; 2016 Sep; 8(10):. PubMed ID: 27669286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
    Benjahad A; Croisy M; Monneret C; Bisagni E; Mabire D; Coupa S; Poncelet A; Csoka I; Guillemont J; Meyer C; Andries K; Pauwels R; de Béthune MP; Himmel DM; Das K; Arnold E; Nguyen CH; Grierson DS
    J Med Chem; 2005 Mar; 48(6):1948-64. PubMed ID: 15771439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of efavirenz (Sustiva) analogues as HIV-1 reverse transcriptase inhibitors: replacement of the cyclopropylacetylene side chain.
    Cocuzza AJ; Chidester DR; Cordova BC; Jeffrey S; Parsons RL; Bacheler LT; Erickson-Viitanen S; Trainor GL; Ko SS
    Bioorg Med Chem Lett; 2001 May; 11(9):1177-9. PubMed ID: 11354371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of the binding energies of efavirenz to wild-type and K103N/Y181C HIV-1 reverse transcriptase based on the ONIOM method.
    Srivab P; Hannongbua S
    ChemMedChem; 2008 May; 3(5):803-11. PubMed ID: 18338369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational approaches for the design of effective human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitors.
    Ribone SR; Quevedo MA; Madrid M; Briñón MC
    J Chem Inf Model; 2011 Jan; 51(1):130-8. PubMed ID: 21133347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors.
    Geitmann M; Unge T; Danielson UH
    J Med Chem; 2006 Apr; 49(8):2367-74. PubMed ID: 16610780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
    Ren J; Nichols CE; Stamp A; Chamberlain PP; Ferris R; Weaver KL; Short SA; Stammers DK
    FEBS J; 2006 Aug; 273(16):3850-60. PubMed ID: 16911530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity predictions for efavirenz analogues with the K103N mutant of HIV reverse transcriptase.
    Udier-Blagović M; Watkins EK; Tirado-Rives J; Jorgensen WL
    Bioorg Med Chem Lett; 2003 Oct; 13(19):3337-40. PubMed ID: 12951121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
    Ren J; Nichols C; Bird L; Chamberlain P; Weaver K; Short S; Stuart DI; Stammers DK
    J Mol Biol; 2001 Sep; 312(4):795-805. PubMed ID: 11575933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored "hydrophobic channel".
    Zhou Z; Liu T; Kang D; Huo Z; Wu G; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    Org Biomol Chem; 2018 Feb; 16(6):1014-1028. PubMed ID: 29349445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.
    Rodríguez-Barrios F; Balzarini J; Gago F
    J Am Chem Soc; 2005 May; 127(20):7570-8. PubMed ID: 15898808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.